Biocorp’s business development team is keeping the pedal to the metal. Days after disclosing news of its deal with Merck KGaA, the delivery systems player revealed a pact with BD to use connected technology to track adherence for self-administered injectable drugs.
The partnership is built on Biocorp’s Injay technology. France-based Biocorp developed the technology to enable companies to add connectivity to prefilled syringes. The device has a near-field communication (NFC) tag on the piston rod that contains information such as the type of drug, concentration, batch number and expiry date.
When the device detects a complete injection, it can send the time-stamped product information to a NFC reader to confirm the delivery of the treatment. Biocorp designed Injay to be adaptable to any size of prefilled syringe.
BD sees the technology as a good fit for its UltraSafe Plus passive needle guard, a device intended to enable single-handed self-administration of injectable medicines. The companies will work to integrate Injay into UltraSafe Plus. Matthew Schabacker, vice president and general manager of advanced drug delivery solutions at BD, explained the thinking behind the integration in a statement.
“Connected drug delivery devices play an important role in helping biopharmaceutical manufacturers understand and track key trends in patient adherence. Our agreement with Biocorp enables us to explore innovative solutions in this market and further supports BD’s commitment to smart, connected care, enabling care to transition to alternate settings and improving chronic disease outcomes,” he said.
The agreement adds BD to a roster of Biocorp partners that also includes Merck KGaA, Novo Nordisk and Sanofi. Biocorp has secured the deals using technology such as Mallya, a clip-on Bluetooth device for use with pen injectors.
By Nick Paul Taylor
Source: fiercepharma.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
